Meeting
2023 ASCO Annual Meeting
Phase II trial of safety and efficacy of tislelizumab plus chemotherapy in stage II-IV non small cell lung cancer (LungMark).
Authors
Yaobin Lin
Department of Thoracic Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, China
Yaobin Lin , You-Hao Chen , Zhi-Chao Lin , Ming Zhou , Wen-Yu Zhai , Ze-Rui Zhao , Bing-Yu Rao , Yu-Heng Zhou , Min Huang , Hao Long
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Local-Regional Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT05244837
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 8564)
DOI
10.1200/JCO.2023.41.16_suppl.8564
Abstract #
8564
Poster Bd #
191
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
A phase II study of paclitaxel and carboplatin plus PD-1 inhibitors combined with anlotinib as first-line treatment for advanced esophageal cancer.
First Author: Mingfang Xu
Poster
2024 ASCO Annual Meeting
Prediction for major pathologic response after neoadjuvant tislelizumab combined with chemotherapy in patients with locally advanced esophageal squamous cell carcinoma by RNA sequencing: A single-arm, phase II trial.
First Author: Wei Guo
Poster
2023 ASCO Annual Meeting
Patient-reported outcomes in patients with metastatic non-squamous non-small cell lung cancer from the PERLA trial comparing first-line chemotherapy plus dostarlimab or pembrolizumab.
First Author: Martin Reck